Allianz Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.47M | Sell |
18,400
-3,000
| -14% | -$247K | ﹤0.01% | 1633 |
|
|
2025
Q4 | $1.82M | Buy |
21,400
+6,200
| +41% | +$509K | ﹤0.01% | 1582 |
|
|
2025
Q3 | $1.18M | Buy |
15,200
+3,300
| +28% | +$258K | ﹤0.01% | 1677 |
|
|
2025
Q2 | $931K | Sell |
11,900
-15,000
| -56% | -$1.12M | ﹤0.01% | 1684 |
|
|
2025
Q1 | $1.95M | Buy |
26,900
+8,400
| +45% | +$601K | ﹤0.01% | 1495 |
|
|
2024
Q4 | $1.37M | Buy |
18,500
+3,800
| +26% | +$266K | ﹤0.01% | 1555 |
|
|
2024
Q3 | $970K | Sell |
14,700
-7,800
| -35% | -$567K | ﹤0.01% | 1641 |
|
|
2024
Q2 | $2.08M | Buy |
22,500
+20,900
| +1,306% | +$1.85M | ﹤0.01% | 1298 |
|
|
2024
Q1 | $153K | Sell |
1,600
-12,000
| -88% | -$1.01M | ﹤0.01% | 1882 |
|
|
2023
Q4 | $1.04M | Sell |
13,600
-17,100
| -56% | -$1.19M | ﹤0.01% | 1587 |
|
|
2023
Q3 | $2.13M | Buy |
30,700
+13,000
| +73% | +$1.04M | ﹤0.01% | 1407 |
|
|
2023
Q2 | $1.67M | Sell |
17,700
-100
| -0.6% | -$8.69K | ﹤0.01% | 1363 |
|
|
2023
Q1 | $1.47M | Buy |
17,800
+12,600
| +242% | +$990K | ﹤0.01% | 1507 |
|
|
2022
Q4 | $388K | Buy |
5,200
+4,600
| +767% | +$355K | ﹤0.01% | 1777 |
|
|
2022
Q3 | $50K | Sell |
600
-5,300
| -90% | -$510K | ﹤0.01% | 1735 |
|
|
2022
Q2 | $561K | Sell |
5,900
-2,700
| -31% | -$280K | ﹤0.01% | 1864 |
|
|
2022
Q1 | $1.01M | Buy |
8,600
+6,100
| +244% | +$684K | ﹤0.01% | 1853 |
|
|
2021
Q4 | $324K | Sell |
2,500
-11,300
| -82% | -$1.32M | ﹤0.01% | 2356 |
|
|
2021
Q3 | $1.56M | Buy |
13,800
+7,300
| +112% | +$833K | ﹤0.01% | 1742 |
|
|
2021
Q2 | $673K | Buy |
+6,500
| New | +$613K | ﹤0.01% | 1909 |
|
|
2020
Q3 | – | Sell |
-47,300
| Closed | -$3.27M | – | 2037 |
|
|
2020
Q2 | $3.27M | Buy |
47,300
+21,200
| +81% | +$1.51M | ﹤0.01% | 1390 |
|
|
2020
Q1 | $1.64M | Sell |
26,100
-18,600
| -42% | -$1.34M | ﹤0.01% | 1595 |
|
|
2019
Q4 | $3.48M | Sell |
44,700
-3,300
| -7% | -$258K | ﹤0.01% | 1647 |
|
|
2019
Q3 | $3.52M | Buy |
48,000
+1,800
| +4% | +$126K | ﹤0.01% | 1604 |
|
|
2019
Q2 | $2.85M | Buy |
46,200
+12,300
| +36% | +$744K | ﹤0.01% | 1748 |
|
|
2019
Q1 | $2.16M | Buy |
33,900
+11,100
| +49% | +$633K | ﹤0.01% | 1820 |
|
|
2018
Q4 | $1.16M | Sell |
22,800
-3,600
| -14% | -$182K | ﹤0.01% | 1968 |
|
|
2018
Q3 | $1.53M | Sell |
26,400
-3,600
| -12% | -$176K | ﹤0.01% | 2056 |
|
|
2018
Q2 | $1.46M | Buy |
30,000
+900
| +3% | +$42K | ﹤0.01% | 2082 |
|
|
2018
Q1 | $1.35M | Sell |
29,100
-81,000
| -74% | -$3.52M | ﹤0.01% | 2087 |
|
|
2017
Q4 | $4.14M | Buy |
110,100
+15,300
| +16% | +$562K | ﹤0.01% | 1713 |
|
|
2017
Q3 | $3.45M | Buy |
94,800
+20,100
| +27% | +$767K | ﹤0.01% | 1794 |
|
|
2017
Q2 | $2.94M | Buy |
74,700
+18,900
| +34% | +$690K | ﹤0.01% | 1845 |
|
|
2017
Q1 | $1.75M | Sell |
55,800
-100,500
| -64% | -$3.15M | ﹤0.01% | 2050 |
|
|
2016
Q4 | $4.88M | Buy |
156,300
+52,800
| +51% | +$1.71M | ﹤0.01% | 1656 |
|
|
2016
Q3 | $4.16M | Buy |
103,500
+17,100
| +20% | +$644K | ﹤0.01% | 1694 |
|
|
2016
Q2 | $2.87M | Buy |
86,400
+44,700
| +107% | +$1.53M | ﹤0.01% | 1758 |
|
|
2016
Q1 | $1.23M | Buy |
41,700
+25,800
| +162% | +$712K | ﹤0.01% | 2006 |
|
|
2015
Q4 | $419K | Buy |
+15,900
| New | +$413K | ﹤0.01% | 2235 |
|
Other funds holding EW
VCM
VPM
Allianz Asset Management's EW Position: Q1 2026 in Review
Allianz Asset Management reduced its Edwards Lifesciences (EW) stake by 10% in Q1 2026, selling an estimated $18.5M and leaving 1,968,211 shares worth $158M. The position accounts for 0.17% of the portfolio, ranked #118.
Allianz Asset Management first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $191M in Q4 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Allianz Asset Management held 1,968,211 shares of Edwards Lifesciences worth $158M as of Q1 2026.
- Allianz Asset Management sold 224,059 Edwards Lifesciences shares in Q1 2026, an estimated $18.5M.
- Edwards Lifesciences made up 0.17% of Allianz Asset Management's portfolio in Q1 2026, its #118 holding.
- Allianz Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Allianz Asset Management's Edwards Lifesciences position peaked at $191M in Q4 2021.
- 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.